irinotecan has been researched along with Carcinoma, Signet Ring Cell in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Batran, SE; Alsina, M; Bang, YJ; Boku, N; Chung, HC; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, KW; Lichinitser, M; Moehler, MH; Park, SH; Ruiz, EY; Ryu, MH; Schenker, M; Taieb, J; Van Cutsem, E; Wyrwicz, L; Xiong, H | 1 |
| Chi, Y; Jiang, ZC | 1 |
| Goto, S; Kamigaki, T; Saito, M; Yano, K | 1 |
| Liu, B; Shen, J; Wang, J; Wang, L; Xie, L | 1 |
| Beaty, K; Choe, JH; Eng, C; Fournier, KF; Mansfield, PF; Ohinata, A; Overman, MJ; Phillips, JK; Rafeeq, S; Royal, RE; Wolff, RA | 1 |
| Hashida, K; Hattori, K; Itou, T; Kai, C; Kawamoto, K; Matsuba, Y; Nagahisa, Y; Sakurai, R | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T | 1 |
| Bae, JM; Choi, IJ; Choi, JY; Chun, JH; Kim, HK; Kim, YW; Lee, HG; Lee, JS; Ryu, KW; Yoon, SM | 1 |
| Hada, M | 1 |
| Hiki, N; Imamura, K; Kaminishi, M; Katayama, A; Mafune, K; Motoi, T; Oohashi, K; Shimizu, N; Shimoyama, S; Yamaguchi, H | 1 |
| Ajani, JA; Andrassy, RJ; Blakely, ML; Harting, MT; Herzog, CE; Lally, KP | 1 |
| Blumenthal, RD; Goldenberg, DM; Hansen, HJ; Hayes, MK; Horak, ID; Osorio, L | 1 |
| Han, MJ; Kang, WK; Kim, HJ; Kwon, JM; Lee, HR; Lee, J; Lim, HY; Oh, SY; Park, BB; Park, JO; Park, YS | 1 |
| Hayashi, T; Kitazaki, T; Kohno, S; Kusakari, C; Matsubara, Y; Nagasaki, T; Nagayasu, T; Nakamura, Y; Nakano, H; Soda, H; Yamaguchi, H | 1 |
| Mohile, SG; Petrylak, DP; Schleicher, L | 1 |
3 trial(s) available for irinotecan and Carcinoma, Signet Ring Cell
| Article | Year |
|---|---|
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Signet Ring Cell; Choice Behavior; Decision Support Techniques; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Stomach Neoplasms; Survival Rate; Young Adult | 2018 |
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2004 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2007 |
14 other study(ies) available for irinotecan and Carcinoma, Signet Ring Cell
| Article | Year |
|---|---|
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cesarean Section; China; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate; Thiophenes | 2018 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium | 2013 |
Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Signet Ring Cell; DNA Methylation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Exodeoxyribonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; RecQ Helicases; Stomach Neoplasms; Sulfatases; Sulfotransferases; Werner Syndrome Helicase | 2013 |
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cetuximab; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Retrospective Studies; Survival Rate; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
[A Case of Signet-Ring Cell Carcinoma of the Sigmoid Colon with Disseminated Carcinomatosis Successfully Treated with CPT-11/Panitumumab].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Camptothecin; Carcinoma, Signet Ring Cell; Disseminated Intravascular Coagulation; Humans; Irinotecan; Male; Panitumumab; Sigmoid Neoplasms | 2015 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2003 |
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Carcinoma, Signet Ring Cell; Celecoxib; Cisplatin; Cyclooxygenase Inhibitors; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Pyrazoles; Sigmoid Neoplasms; Sulfonamides; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
[Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Carcinoma, Signet Ring Cell; Cholecystectomy; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Middle Aged; Neoplasms, Multiple Primary; Splenectomy; Stomach Neoplasms | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Catheter Ablation; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplastic Syndromes, Hereditary; Pancreatectomy; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Reoperation; Splenectomy; Stomach Neoplasms; Taxoids | 2004 |
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; Complement System Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Survival Rate; Transplantation, Heterologous | 2005 |
Mediastinal signet-ring cell carcinoma of unknown primary: long-term survival by treatment with S-1, a novel derivative of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Drug Combinations; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2007 |
Treatment of metastatic urachal carcinoma in an elderly woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Cystectomy; Diagnosis, Differential; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Neoplasm Recurrence, Local; Pelvic Neoplasms; Radiotherapy, Adjuvant; Urachus; Urinary Bladder Neoplasms | 2008 |